Evaxion Biotech A/S (EVAX)

Market Cap	9.16M
Revenue (ttm)	3.34M
Net Income (ttm)	-10.57M
Shares Out	6.32M
EPS (ttm)	-9.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,068
Open	1.460
Previous Close	1.480
Day's Range	1.430 - 1.500
52-Week Range	1.200 - 20.810
Beta	-0.23
Analysts	Strong Buy
Price Target	10.00 (+589.66%)
Earnings Date	May 27, 2025

About EVAX

Evaxion Biotech A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also inclu...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://evaxion.ai

Financial Performance

In 2024, Evaxion Biotech's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 589.66% from the latest price.

Price Target

$10.0

(589.66% upside)

Analyst Consensus: Strong Buy